Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scalp psoriasis drug shows promise in Late-Stage trial

NCT ID NCT05478499

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 22 times

Summary

This study tested whether the drug deucravacitinib can safely and effectively treat moderate-to-severe scalp psoriasis compared to a placebo. About 154 adults with stable plaque psoriasis affecting the scalp took part. The main goal was to see how many achieved clear or almost clear scalp skin after 16 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    Hot Springs, Arkansas, 71913, United States

  • Local Institution - 0002

    New Brighton, Minnesota, 55432, United States

  • Local Institution - 0003

    Portland, Oregon, 97201, United States

  • Local Institution - 0004

    San Antonio, Texas, 78229, United States

  • Local Institution - 0005

    Pittsburgh, Pennsylvania, 15213, United States

  • Local Institution - 0006

    Norfolk, Virginia, 23502, United States

  • Local Institution - 0007

    Indianapolis, Indiana, 46256, United States

  • Local Institution - 0008

    Beverly, Massachusetts, 01915, United States

  • Local Institution - 0011

    Mahlow, 15831, Germany

  • Local Institution - 0012

    Lübeck, 23538, Germany

  • Local Institution - 0013

    Frankfurt am Main, Hesse, 60590, Germany

  • Local Institution - 0014

    Rzeszów, 35-055, Poland

  • Local Institution - 0015

    Wroclaw, 51-685, Poland

  • Local Institution - 0017

    Lodz, 90-436, Poland

  • Local Institution - 0019

    Paris, 75010, France

  • Local Institution - 0022

    Rockville, Maryland, 20850, United States

  • Local Institution - 0026

    Krakow, 30438, Poland

  • Local Institution - 0031

    London, Greater London, SE1 9RT, United Kingdom

  • Local Institution - 0033

    Houston, Texas, 77004, United States

  • Local Institution - 0038

    Witten, Deutschland, 58454, Germany

  • Local Institution - 0039

    Southampton, HAMPSHIRE, SO16 6DU, United Kingdom

  • Local Institution - 0040

    Romans-sur-Isère, 26102, France

  • Local Institution - 0041

    Louisville, Kentucky, 40217, United States

  • Local Institution - 0044

    Rouen, 76031, France

  • Local Institution - 0045

    Salford, Greater Manchester, M6 8HD, United Kingdom

  • Local Institution - 0047

    Bloomfield Hills, Michigan, 48302, United States

  • Local Institution - 0048

    Hamburg, 20246, Germany

  • Local Institution - 0049

    East Windsor, New Jersey, 08520, United States

  • Local Institution - 0051

    Kew Gardens, New York, 11415, United States

Conditions

Explore the condition pages connected to this study.

PSORIASIS